A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab for the Treatment Of Recurrent or Progressive Glioblastoma That Has Progressed on Bevacizumab
Angiogenesis plays a central role in the progression of solid cancer. TRC105 is an antibody
to CD105, an important non-VEGF angiogenic target on proliferating endothelial cells. TRC105
inhibits angiogenesis, tumor growth and metastases in preclinical models. TRC105 has been
well tolerated in patients with glioblastoma (GBM) as a single agent. The combination of
TRC105 in combination with bevacizumab has demonstrated activity in bevacizumab refractory
cancer patients. We hypothesize that TRC105 when administered with bevacizumab will have
activity in GBM patients who progress on bevacizumab. By targeting a non-VEGF pathway,
TRC105 has the potential to complement VEGF inhibition by bevacizumab, which could represent
a major advance in GBM therapy.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Determine median overall survival (OS) in patients with recurrent or progressive GBM who have progressed on bevacizumab.
United States: Food and Drug Administration
|University Hospitals of Cleveland||Cleveland, Ohio 44106|
|Cleveland Clinic||Cleveland, Ohio 44195|
|University of Cincinnati||Cincinnati, Ohio 45267-0502|